NCT06564155Not yet recruiting
Inturlekin L33 in Ankylosing Spondylities Patients and Its Relation to Subclinical Atherosclerosis
Inturlekin 33 in Ankylosing Spondylitis Patients and Its Relationship to Subclinical Atherosclerosis
Source: ClinicalTrials.gov · Last updated 22 Aug 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
detect level of Inturlekin 33 in ankylosing spondyilits patient measure CIMT (carotid intima media thickness ) by carotid duplex to detect subclinical atherosclerosis in ankylosing spondyitis patients detect the relation between IL33 and subclinical atherosclerosis in Ankylosinig Spondylitis patients
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 45 (estimated)
- First submitted
- 19 Aug 2024
- Start date
- Sept 2024
- Primary completion date
- Aug 2026
- Lead sponsor
- Assiut University
- Diseases
- Ankylosing spondylitis
- NCT number
- NCT06564155
What you commit to
- Study type: Observational
- Planned participants: 45
- From Sept 2024 to the primary completion date, Aug 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with other rheumatic diseases/other SPA types
- Participants with history of CVD event in past or present
- Patient experiencing cardiovascular revascularization surgery or cerebrovascular disorder within past 6 months.
- Patient with other risk factor for atherosclerosis.
Who the study is looking for
- patient diagnosed as Ankylosing Spondylitis
- Age (20-40)
Age in the registry: 20 years to 40 years · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.